Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | G6PD | P11413 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2962995 | 0.85 | ALDH1A1 (0.39) | LMNAALDH1A1HSD17B10NPC1RAB9A | |
| SCHEMBL2960589 | 0.81 | ALDH1A1 (0.49) | LMNAALDH1A1HSD17B10NPC1RAB9A | |
| SCHEMBL2968217 | 0.79 | ALDH1A1 (0.50) | LMNAALDH1A1HSD17B10KDM4ENPC1 | |
| SCHEMBL5397717 | 0.72 | ALDH1A1 (0.57) | LMNAALDH1A1HSD17B10KDM4ESMN1; SMN2 | |
| SCHEMBL9427620 | 0.70 | SMN1; SMN2 (0.41) | KDM4ESMN1; SMN2CYP2C9MEN1KMT2A | |
| SCHEMBL1970540 | 0.67 | ALDH1A1 (0.41) | LMNAALDH1A1HSD17B10NPC1RAB9A | |
| SCHEMBL2962997 | 0.66 | ALDH1A1 (0.44) | ALDH1A1HSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL294581 | 0.65 | LMNA (0.40) | LMNAALDH1A1HSD17B10KDM4ERAB9A | |
| SCHEMBL10016387 | 0.64 | RAB9A (0.73) | LMNAALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL15212810 | 0.64 | ALDH1A1 (0.54) | LMNAALDH1A1HSD17B10SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772257-B2 | Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, processes for their preparation, pharmaceutical compositions and methods for their use | SANOFI-AVENTIS (FR) | 2010-08-10 | — | — | US | disclosed |
| US-20100022603-A1 | BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | SANOFI-AVENTIS (FR) | 2010-01-28 | — | — | US | disclosed |
| US-7612104-B2 | Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, processes for their preparation, pharmaceutical compositions and methods for their use | SANOFI-AVENTIS (FR) | 2009-11-03 | — | — | US | disclosed |
| US-20080293780-A1 | BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | SANOFI-AVENTIS (FR) | 2008-11-27 | — | — | US | disclosed |
| EP-1937675-A2 | BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007039174-A2 | BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293780-A1 | BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | PPARG, PPARA, PPARD | LMNA 2553/4885ALDH1A1 1019/4885HSD17B10 617/4885 |
| US-20100022603-A1 | BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | PPARG, PPARA, PPARD | LMNA 2614/4885ALDH1A1 1072/4885HSD17B10 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.